Pharmaceuticals
RNAGENE Signs a Collaborative Research Agreement with PharmAbcine to Develop Novel mRNA Therapeutics
SEOUL, South Korea, March 21, 2022 /PRNewswire/ -- RNAGene Inc., a South Korean biotech which specializes in the development of mRNA (messenger ribonucleic acid)-based therapeutics, announced today that it has signed a Collaborative Research Agreement with PharmAbcine Inc. (KOSDAQ: 208340ks), a c...
2022-03-21 20:00
1759
Nuance Pharma Announces License and Supply Agreement with Bavarian Nordic on the Development and Commercialization of Respiratory Syncytial Virus (RSV) Vaccine for Adults in China and Selected Asian Markets
* Bavarian Nordic to receive up to USD 225 million in upfront and milestone payments in addition to tiered, double-digit royalties * Nuance Pharma obtains rights to commercialize MVA-BN® RSV in Chinese Mainland,Hong Kong, Macau, Taiwan, South Korea and Southeast Asia and will be responsible f...
2022-03-21 16:20
1659
Progresses Made in Series of Studies of Prevention and Control of COVID-19 with Lianhua Qingwen Capsules
SHIJIAZHUANG, China, March 21, 2022 /PRNewswire/ -- On March 19, the Media Briefing on Prevention and Control of COVID-19 with Lianhua Qingwen Capsules, a patented Chinese medicine developed and produced by Yiling Pharmaceutical, was convened inShijiazhuang City, Hebei Province, at which the in v...
2022-03-21 15:56
1958
Recbio Announces Proposed Listing on the Main Board of the Hong Kong Stock Exchange
Offer Price of HK $24.80 per H Share To Raise Proceeds Up to HK$765 Million Focus on the R&D of HPV Vaccine Candidates Focus on In-house Research and Development of Novel Vaccines TAIZHOU, China, March 21, 2022 /PRNewswire/ -- The China-based novel vaccines company -Jiangsu Recbio Technology Co....
2022-03-21 14:41
3140
I-Mab to Report Full Year 2021 Financial Results and Provide Corporate Update on March 29, 2022
SHANGHAI and GAITHERSBURG, MD, March 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company will report financial results for the ...
2022-03-18 20:00
3588
Lynk Pharmaceuticals and Simcere announced Strategic Commercialization Partnership upon novel JAK1 inhibitor LNK01001
HANGZHOU, China, March 18, 2022 /PRNewswire/ -- On March 18, 2022, Lynk Pharmaceuticals Co., Ltd. (Lynk Pharmaceuticals) and Simcere (2096.HK) announced a strategic partnership to develop and commercialize a highly selective JAK1 inhibitor LNK01001 inChina. Under the terms of the agreement, Lynk...
2022-03-18 13:28
5943
CStone Pharmaceuticals Announces the Acceptance of New Drug Application (NDA) for Pralsetinib for the Treatment of RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) in Hong Kong, China
SUZHOU, China, March 18, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, announced today that the new drug application (...
2022-03-18 10:35
2979
CStone announced the global multi-regional registration trial of anti-PD-1 antibody nofazinlimab in combination with lenvatinib as first-line treatment for patients with advanced hepatocellular carcinoma successfully reached the prespecified enrollment target
SUZHOU, China, March 18, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the global multi-regional ...
2022-03-18 08:37
3294
Led by OrbiMed, HiRO Raised Tens of Millions of US Dollars in Series A Financing, to Offer Multinational Global Clinical Development Strategy
SHANGHAI, March 18, 2022 /PRNewswire/ -- Harvest Integrated Research Organization ("HiRO" or the "Company") announced the completion of its Series A financing in the tens of millions of US dollars. This round of investment is led by OrbiMed, with the participation from existing shareholder, Fontu...
2022-03-18 08:00
3305
China CDE Approved First Universal CAR-T IND !
NANJING, China, March 17, 2022 /PRNewswire/ -- On March 17, 2022, China National Drug Administration Drug Review Center (CDE) approved first Universal Chemeric Antigen Receptor T (UCAR-T) cell drug (Acceptance No. : CXSL2101509). CTA101 is independently developed by Nanjing Bioheng Biotech Co., L...
2022-03-17 21:32
1672
Triastek and Siemens announce strategic collaboration to accelerate digital transformation of the pharmaceutical industry
NANJING, China, March 17, 2022 /PRNewswire/ -- Triastek, Inc. and Siemens Ltd., China have signed a strategic collaboration agreement to provide digital technologies for the global pharmaceutical industry. Combining Triastek's industry-leading 3D printing and digital pharmaceutical technologies a...
2022-03-17 21:24
2462
BioVaxys Announces Bioproduction of BVX-1021 for its Pan-Sarbecovirus Program in Collaboration with The Ohio State University
VANCOUVER, BC, March 17, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that it has entered into an agreement with Millipore-Sigma ("Millipore") a global Contract Development and Manufacturing Research Organization (...
2022-03-17 20:18
3346
Seegene appoints Dr. Glen Hansen as Head of Medical Affairs of U.S. subsidiary
SEOUL, South Korea, March 17, 2022 /PRNewswire/ -- Seegene Inc.
2022-03-17 20:00
1625
First eye drops registered on the Australian Register of Therapeutic Goods (ARTG) to slow the progression of short-sightedness now available for children aged from 4 to 14 years old[1]
SYDNEY, March 17, 2022 /PRNewswire/ -- Aspen announced the Therapeutic Goods Administration (TGA) listing of a new medication to slow the progression of short-sightedness (myopia) in children and young teenagers. EIKANCE® 0.01% eye drops (atropine sulfate monohydrate 0.01%) are available on presc...
2022-03-17 17:00
2782
KeyZell start-up plans to reach 5 million euros in private investment and become the new biotech unicorn
MADRID, March 17, 2022 /PRNewswire/ -- KeyZell, a Spanish biotechnology company in the development phase of digital cancer treatments and tools, has just opened a private financing round which expects to achieve5 million euros to boost its projects and consolidate itself as one of the biotech sta...
2022-03-17 15:30
2859
111, Inc. Announces Fourth Quarter and Fiscal Year 2021 Financial Results
SHANGHAI, March 17, 2022 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced its unaudited financial results for the fourth qua...
2022-03-17 15:20
2238
Henlius 2021 Annual Results: New Record in Performance, Evolving to Biopharma
SHANGHAI, March 17, 2022 /PRNewswire/ -- Henlius (2696.HK) announced its annual results for the year endedDecember 31st, 2021, sharing the company's recent noteworthy progress and achievements. As a global innovative biopharmaceutical company, Henlius is committed to offering high-quality, afford...
2022-03-17 08:00
3504
Henlius 2021 Annual Results: New Record in Performance, Evolving to Biopharma
SHANGHAI, March 16, 2022 /PRNewswire/ -- Henlius (2696.HK) announced its annual results for the year endedDecember 31st, 2021, sharing the company's recent noteworthy progress and achievements. As a global innovative biopharmaceutical company, Henlius is committed to offering high-quality, afford...
2022-03-16 23:46
2077
Adagene Announces FDA Clearance to Proceed with Phase 1b/2 Trial of Anti-CTLA-4 ADG126 SAFEbody® in Combination Therapy With Anti-PD-1 Antibody Pembrolizumab
SAN DIEGO and SUZHOU, China, March 16, 2022 /PRNewswire/ -- Adagene Inc. ("Adagene") (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced FDA clearance to proceed with a Phase1b/2 clinical trial of its anti-CTLA-4 monoclonal antib...
2022-03-16 19:00
2776
SSI SCHAEFER and Nahdi Medical Company launch the Middle East's first Automated Pharmaceutical Distribution Center facility in Saudi Arabia
RIYADH，Saudi Arabia, March 16, 2022 /PRNewswire/ -- SSI SCHAEFER
2022-03-16 15:00
2195
Week's Top Stories
Most Reposted
LONG AN INTERNATIONAL PORT JOINS 12TH PORTECH ASIA SUMMIT 2025 IN MALAYSIA
[Picked up by 337 media titles]
2025-01-18 03:30
Supported by the Luxembourg Government, The Luxembourg House of Financial Technology (LHoFT) and the Asian Development Bank (ADB) Announce the 2nd Edition of Catapult | SE Asia 2025
[Picked up by 312 media titles]
2025-01-22 15:38
Hong Kong Airlines Takes Off to Australia's Gold Coast Bringing Popular Travel Option for the Chinese New Year
[Picked up by 311 media titles]
2025-01-18 17:00
dss⁺ Announces Strategic Changes to Executive Leadership Team in Asia Pacific Accelerating growth and impact for high-hazard industries in the region
[Picked up by 309 media titles]
2025-01-21 16:00
HARD ROCK HOTEL BALI ACHIEVES PRESTIGIOUS GSTC CERTIFICATION
[Picked up by 306 media titles]
2025-01-20 14:27
Most Read
LONG AN INTERNATIONAL PORT JOINS 12TH PORTECH ASIA SUMMIT 2025 IN MALAYSIA
2025-01-18 03:30
12387
Hong Kong Airlines Takes Off to Australia's Gold Coast Bringing Popular Travel Option for the Chinese New Year
2025-01-18 17:00
11590
Boosting Yeast Protein Production to Meet the Growing Global Demand for Alternative Proteins
2025-01-17 22:46
10227
Dongying's vibrant Spring Festival awaits visitors
2025-01-17 21:46
10088